<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511378</url>
  </required_header>
  <id_info>
    <org_study_id>LRP/PegGCSF/2016/004</org_study_id>
    <nct_id>NCT03511378</nct_id>
  </id_info>
  <brief_title>Assessment of the Immunogenicity of Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer</brief_title>
  <official_title>An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lupin Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lupin Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the immunogenicity of Peg-filgrastim versus Neulasta®
      as an adjunct to chemotherapy in patients with breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">March 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Immunogenicity Endpoint: Cumulative Incidence of anti-pegfilgrastim antibodies (binding &amp; neutralizing) at the end of cycle 4 (Day 84)</measure>
    <time_frame>End of cycle 4, Day 84</time_frame>
    <description>The difference in the proportion of patients with cumulative incidence of anti-pegfilgrastim antibodies (binding &amp; neutralizing) to Pegfilgrastim between study groups at the end of cycle 4 (Day 84) will be calculated. Those samples confirmed to be positive for binding antibodies will be analyzed for presence of neutralizing antibodies to Pegfilgrastim.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Immunogenicity endpoint: Incidence of anti-pegfilgrastim antibodies (binding &amp; neutralizing) on Day 10, Day 21, Day 42, Day 63 and Day 84.</measure>
    <time_frame>Day 10, Day 21, Day 42, Day 63 and Day 84.</time_frame>
    <description>Presence of anti-pegfilgrastim antibodies at the end of each cycle will be analyzed for each patient. Those samples confirmed to be positive for binding antibodies will be analyzed for presence of neutralizing antibodies to Pegfilgrastim.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Immunogenicity endpoint: Cumulative Incidence of anti-peg antibodies (binding &amp; neutralizing) at the end of cycle 4 (Day 84).</measure>
    <time_frame>End of cycle cycle 4, day 84</time_frame>
    <description>Presence of anti-peg antibodies at the end of each cycle will be analyzed for each patient. Those samples confirmed to be positive for binding antibodies will be analyzed for presence of neutralizing antibodies to Pegfilgrastim.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Immunogenicity Endpoint: Incidence of anti-peg antibodies (binding &amp; neutralizing) on Day 10, Day 21, Day 42, Day 63 and Day 84.</measure>
    <time_frame>Day 10, Day 21, Day 42, Day 63 and Day 84.</time_frame>
    <description>Presence of anti-peg antibodies at the end of each cycle will be analyzed for each patient. Those samples confirmed to be positive for binding antibodies will be analyzed for presence of neutralizing antibodies to Pegfilgrastim.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint: Incidence of AEs over time to end of study</measure>
    <time_frame>Through end of cycle 4, day 84 or early discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, Respiratory rate : Number of patients with clinically meaningful changes from baseline in vital signs over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Respiratory rate (breaths/minute) will be measured. Number of patients with clinically meaningful changes in respiratory rate from baseline over the time period will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, Body Temperature: Number of patients with clinically meaningful changes from baseline in vital signs over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Axillary body temperature (degree Celsius or Fahrenheit) will be measured. Number of patients with clinically meaningful changes in axillary body temperature from baseline over the time period will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, Pulse rate: Number of patients with clinically meaningful changes from baseline in vital signs over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Pulse rate (heart beats/minute) will be measured. Number of patients with clinically meaningful changes in pulse rate from baseline over the time period will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, Blood pressure: Number of patients with clinically meaningful changes from baseline in vital signs over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Blood pressure will be measured (mm Hg). Number of patients with clinically meaningful changes in blood pressure from baseline over the time period will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint: Number of patients with abnormal clinically significant physical examination findings over the period.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Physical examinations will include, but are not limited to, the below items: General findings, HEENT exam (head, eyes, ears, nose and throat), assessment of respiratory, cardiovascular, gastrointestinal, nervous, musculoskeletal and renal/ urinary systems, lymph nodes and dermatologic examination (including skin appendages) and other findings/ physical conditions of note. Number of patients with Abnormal clinically significant physical examination findings over the time period will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, hematology: Number of patients with clinically meaningful abnormal clinical laboratory findings over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Number of patients with clinically meaningful abnormal clinical laboratory findings over the time period will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, blood biochemistry: Number of patients with clinically meaningful abnormal clinical laboratory findings over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>Number of patients with clinically meaningful changes in blood chemistry from baseline over the time period will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint, urinanalysis: Number of patients with clinically meaningful abnormal clinical laboratory findings over the time.</measure>
    <time_frame>Through end of cycle cycle 4, day 84 or early discontinuation</time_frame>
    <description>The number of patients with clinically meaningful abnormal clinical laboratory findings over the time period will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lupin's Pegfilgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lupin's Pegfilgrastim</intervention_name>
    <description>Administration of Pegfilgrastim</description>
    <arm_group_label>Lupin's Pegfilgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta®</intervention_name>
    <description>Administration of Neulasta®</description>
    <arm_group_label>Neulasta®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able and willing to give written informed consent prior to any study
             related procedures

          2. Ambulatory, female patients with an age ≥ 18 years

          3. Patients with histologically or cytologically proven diagnosis of breast cancer who
             are eligible for neoadjuvant or adjuvant chemotherapy.

          4. Patients who are planned and eligible to receive/ receiving myelosuppressive
             chemotherapy regimen that contains at least one chemotherapeutic agent from docetaxel/
             paclitaxel / doxorubicin/ cyclophosphamide/ epirubicin

          5. Patients who have not received any hematopoietic growth factors (e.g. G-CSF, PegGCSF,
             erythropoietin) or cytokines (e.g. interleukins, interferons) anytime in the past

          6. Patients with baseline WBC ≥ LLN/ 3.5 x 109/L, ANC of ≥ 1.5 x 109/L, platelet count ≥
             100 x 109/L and hemoglobin ≥ 8.5 g/dL

          7. Patients with ECOG Performance status of ≤ 2

          8. Patient who have estimated life expectancy of more than six months

          9. No evidences of hemorrhage

        Exclusion Criteria:

        1 Male patients

        2. Hypersensitivity to any of the study drugs or its components like E.coli proteins or
        similar product

        3. Patients weighing &lt;45 Kg

        4. Patients with myeloid malignancies and myelodysplasia or evidence of metastatic disease
        in bone marrow or brain

        5. Patients currently receiving radiation therapy or have completed radiation therapy
        within 4 weeks before study entry or likely to receive radiotherapy during the study

        6. Patients with prior bone marrow or stem cell transplantation

        7. Patients with chronic use of oral corticosteroids (Except ≤ 20 mg/day dose of
        prednisolone/ equivalent steroids), immunotherapy, monoclonal antibody therapy and/or
        biological therapy or use of any other pegylated drug.

        8. Patients with history of systemic antibiotic use within 72 hours prior to chemotherapy

        9. Patients with any active infection which may require systemic antimicrobial therapy.
        Patients with inadequate hepatic and renal function [defined as Alkaline Phosphatase &gt; 2.5
        X Upper limits of normal (ULN), serum SGOT &gt; 2.5 X ULN, SGPT &gt; 2.5 X ULN, Total bilirubin &gt;
        1.5 X ULN and Creatinine &gt; 1.5 X ULN of the reference range at the screening assessment]

        10. Patients with seropositivity for HIV or HBV or HCV

        11. Known cases of Sickle Cell Anemia

        12. Patients with radiographic evidence of active pulmonary infections and/or recent
        history of pneumonia within 1 month of screening

        13. Patients with clinically evident splenomegaly confirmed subsequently by ultrasonography

        14. Patients with any other clinically significant disease(s) which, in the opinion of the
        investigator, could compromise the patient's involvement in the study or overall
        interpretation of the data. [for e.g. uncontrolled hematologic, renal, hepatic, endocrine,
        neurologic, psychiatric, metabolic, pulmonary, cardiovascular disease/impaired functioning
        or history of any autoimmune disease]

        15. Patients who have participated in another therapeutic clinical study within the past 30
        days prior to screening, or are likely to simultaneously participate in another therapeutic
        clinical study

        16. Patients who are doubtful to comply with study procedures for mental, psychological or
        social reasons.

        17. Women of child-bearing potential who are not willing to follow a reliable &amp; effective
        contraceptive measure during the course of the study &amp; at least 3 months after the last
        dose of study drug.

        18. Pregnant and Breast feeding women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dhananjay Bakhle, MD</last_name>
    <phone>+91-20-66749054</phone>
    <email>dhananjaybakhle@lupin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Apple Hospital</name>
      <address>
        <city>Sūrat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast neoplasms</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of Breast</keyword>
  <keyword>Anti-Drug Antibodies (ADA)</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

